Jeffrey M. Jonas - Jun 15, 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey M. Jonas
Stock symbol
SAGE
Transactions as of
Jun 15, 2023
Transactions value $
$0
Form type
4
Date filed
6/16/2023, 04:06 PM
Previous filing
Jun 12, 2023
Next filing
Jun 22, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +10K $0.00 10K Jun 15, 2023 Common Stock 10K $56.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 15, 2024 or the day immediately prior to the 2024 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.